31 research outputs found
Treatment of breast cancer
Compounds of the class of 4-oxo-butenoic acid derivatives are disclosed along with the surprising use property of these compounds as a anti-tumor agents in humans against breast carcinoma, which include: 2-(N\u27-Fluoren-9-ylidene-hydrazino)-5,5-dimethyl-4-oxo-hex-2-enoic acid methyl ester (OF-06), 1-(2,4-Dimethyl-phenyl)-2,4-dihydroxy-3-4-methyl-benzoyl)-5-oxo-2,5-dihydro-1H-pyrrole-2-carboxylic acid methyl ester (1F-07), 4-(4-Methoxy-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid (3F-10), 4-(4-Chloro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid ethyl ester (3F-11), 2-Hydroxy-4-oxo-4-(2,3,5,6-tetrafluoro-4-methoxy-phenyl)-but-2-enoic acid (3F-15), and 4,4-Dihydroxy-5-4-methyl-benzoyl)-2-phenyl-2,4-dihydro-pyrazol-3-one (3F-16) as well as some novel derivatives of these compounds claimed (see Table 2). The invention also encompasses a class of the compounds with the novel property of anti-tumor activity against human breast cancer, which includes the following compounds 4-(4-Ethoxy-phenyl)-2-(N\u27-fluoren-9-ylidene-hydrazino)-2-hydroxy-4-oxo-butyric acid methyl ester (OF-13); 2-{N\u27-[1-(4-Chloro-phenyl)-ethylidene]-hydrazino}-4-oxo-4-phenyl-but-2-enoic acid methyl ester (OF-20); 2-(N\u27-Fluoren-9-ylidene-hydrazino)-4-oxo-4-phenyl-but-2-enoic acid methyl ester (1F-04); and 4-Chloro-4-(4-ethoxy-phenyl)-2-(fluoren-9-ylidene-hydrazono)-but-3-enoic acid methyl ester (3F-19)
Treatment of breast cancer
Compounds of the class of 4-oxo-butenoic acid derivatives are disclosure along with the surprising use property of these compounds as an anti-tumor agents in humans against breast carcinoma, which includes; 2-(N\u27-Fluoren-9-ylidene-hydrazino)-5,5-dimethyl-4-oxo-hex-enoic acid methyl ester (OF-06), 1-(2,4-Dimethyl-phenyl)-2,4-dihydroxy-3-(4-methyl-benzoyl)-5-oxo-2,5-dihydro-1H-pyrrole-2-carboxylic acid methyl ester (IF-07), 4-(4-Methoxy-phenyl)-2,4-dioxo-3-(phenyk-hydrazono)-butyric acid (3F-10, 4-(4-Chloro-phenyl)-2,4-dioco-3-(phenyl-hydrzono)-butyric acid ehtyl ester (3F-11), 2-Hyroxy-4-oxo-4-(2,3,5,6-tetrafluoro-4-methoxy-phenyl)-but-2-enoic acid (3F-15), and 4, 4-Dihyroxy-5-(4-methyl-benzoyl)-2-phenyl-2,4-dihdro-pyrazol-3-one (3F-16) as well as some novel derivatives of these compounds claimed. The invention also encompasses a class of the compounds with the novel property of anti-tumor activity agains human breast cancer, which includes the following compounds4-(4-Ethoxy-phenyl)-2-(N\u27-[1-(4-Chloro-phenyl)-ethylidene-hydrazino-2-hydroxy-4-oxo-butyric acid methyl ester (OF-13); 2-{N\u27-[1-(4-Chloro-phenyl)-ethylidene]-hydrazino]-4-oxo-4-phenyl-but-2-enoic-acid methyl ester (1F-04); amd 4-Chloro-4-(4-ethoxy-phenyl)-2-(fluoren-9-ylidene-hydrazono)-but-3-enoic acid methyl ester (3F-19)
Π ΠΎΡΡΠΈΠΉΡΠΊΠΈΠ΅ ΡΠΎΡΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ ΠΏΡΠΈΡ ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ΅ΠΌΡΠΈ Π² XXI Π²Π΅ΠΊΠ΅: ΠΌΠ΅ΡΠ°-Π°Π½Π°Π»ΠΈΠ·
Π ΡΡΠ°ΡΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ Π°Π½Π°Π»ΠΈΠ· ΡΠΏΠ΅ΡΠΈΡΠΈΠΊΠΈ ΠΏΡΠ±Π»ΠΈΠΊΠ°ΡΠΈΠΉ Π² ΡΠΎΡΡΠΈΠΉΡΠΊΠΈΡ
ΡΠΎΡΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ ΠΏΡΠΈΡ
ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π½Π°ΡΡΠ½ΡΡ
ΠΆΡΡΠ½Π°Π»Π°Ρ
, ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ΅ΠΌΡΠΈ. ΠΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ ΡΠ΅ΠΊΡΡΡ ΡΠ΅ΡΡΡΠ΅Ρ
Π½Π°ΡΡΠ½ΡΡ
ΠΈΠ·Π΄Π°Π½ΠΈΠΉ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠ΅Π³ΠΎ ΠΏΡΠΎΡΠΈΠ»Ρ Π·Π° 2000-2016 Π³Π³. ΠΠ°Π½Π½ΡΠ΅ ΡΡΠΎΠ³ΠΎ ΠΎΠ±Π·ΠΎΡΠ° ΡΠ°ΡΡΠΈΡΠ½ΠΎ ΡΠΎΠΏΠΎΡΡΠ°Π²ΠΈΠΌΡΠΌΠΈ Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌΠΈ Π°Π½Π°Π»ΠΈΠ·Π° ΡΡΠ°ΡΠ΅ΠΉ Π·Π° 1986-1991 Π³Π³., ΡΡΠΎ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΎΡΠ΅Π½ΠΈΡΡ Π½Π΅ΠΊΠΎΡΠΎΡΡΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ. ΠΠ° ΠΎΡΠ½ΠΎΠ²Π΅ ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ-ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° ΡΡΠ΄Π° ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΡΠ΄Π΅Π»Π°Π½Ρ Π²ΡΠ²ΠΎΠ΄Ρ ΠΎ ΡΠΏΠ΅ΡΠΈΡΠΈΠΊΠ΅ Π½Π°ΡΡΠ½ΡΡ
ΠΏΠ°ΡΠ°Π΄ΠΈΠ³ΠΌ ΠΈ ΡΠΎΡΡΠΎΡΠ½ΠΈΠΈ Β«βΠ½ΠΎΡΠΌΠ°Π»ΡΠ½ΠΎΠΉβ Π½Π°ΡΠΊΠΈΒ» (ΠΏΠΎ Π’. ΠΡΠ½Ρ) ΠΏΡΠΈΠΌΠ΅Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΊ ΡΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ ΡΠΎΡΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΏΡΠΈΡ
ΠΎΠ»ΠΎΠ³ΠΈΠΈ ΡΠ΅ΠΌΡΠΈ. ΠΠ»Ρ ΠΏΠΎΡΠ»Π΅Π΄Π½Π΅ΠΉ ΡΠ΅ΠΌΡΡ, ΡΡΠ΄Ρ ΠΏΠΎ ΠΏΡΠ±Π»ΠΈΠΊΠ°ΡΠΈΡΠΌ Π² Π½Π°ΡΡΠ½ΡΡ
ΠΆΡΡΠ½Π°Π»Π°Ρ
, β ΠΌΠ°Π»ΠΎΠ·Π½Π°ΡΠΈΠΌΡΠΉ ΠΎΠ±ΡΠ΅ΠΊΡ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ, ΠΎΠ½Π° ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°Π΅ΡΡΡ ΠΊΠ°ΠΊ ΡΠΎΠ½ Π΄Π»Ρ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ Π»ΠΈΡΠ½ΠΎΡΡΠΈ (ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΡΠ΅Π±Π΅Π½ΠΊΠ°) ΠΈ ΠΌΠ΅ΠΆΠ»ΠΈΡΠ½ΠΎΡΡΠ½ΡΡ
ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΉ. ΠΠ΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΠΎΡΡΡ ΡΠ°ΠΊΠΎΠ³ΠΎ ΠΎΠ±ΡΠ΅ΠΊΡΠ° ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΎΠ±ΡΡΠ»Π°Π²Π»ΠΈΠ²Π°Π΅Ρ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΡΠΉ ΠΈΠ½ΡΠ΅ΡΠ΅Ρ ΠΏΡΠΈΡ
ΠΎΠ»ΠΎΠ³ΠΎΠ² ΠΊ ΠΌΠ΅ΡΠΎΠ΄ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΡΠ½Π°ΡΠ΅Π½Π½ΠΎΡΡΠΈ ΠΈ Π±ΠΎΠ»ΡΡΠ΅ΠΌΡ ΡΠ°Π·Π½ΠΎΠΎΠ±ΡΠ°Π·ΠΈΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΡΠ±ΠΎΡΠ° ΡΠΌΠΏΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π°Π΅ΡΡΡ ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠ°ΡΠΈΠ΅ΠΉ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΎΠΎΠ±ΡΠ΅ΡΡΠ²Π° ΠΏΠΎ Β«ΡΠΊΠΎΠ»ΡΠ½ΠΎ-ΠΆΡΡΠ½Π°Π»ΡΠ½ΠΎΠΌΡΒ» (ΡΠ΅ΡΡ Π·Π΄Π΅ΡΡ ΠΏΡΠΎ Π½Π°ΡΡΠ½ΡΠ΅ ΡΠΊΠΎΠ»Ρ) ΠΏΡΠΈΠ½ΡΠΈΠΏΡ. Π ΡΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ ΡΠΎΡΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ ΡΠ΅ΠΌΡΠΈ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΡΠ΅ΠΌΡΠΈ Π²Π°ΡΡΠΈΡΡΠ΅Ρ, Π½ΠΎ Π΅Π΅ ΠΏΠ°ΡΠ°Π΄ΠΈΠ³ΠΌΠ° Π΄ΡΠ°Π»ΠΈΡΡΠΈΡΠ½Π° (ΠΏΡΠΈ Π΄ΠΎΠΌΠΈΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ Π΅ΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ-Π½Π°ΡΡΠ½ΠΎΠΉ); Π±ΠΎΠ»Π΅Π΅ ΡΠΎΠ³Π»Π°ΡΠΎΠ²Π°Π½Π° ΠΈ ΡΡΠ°Π±ΠΈΠ»ΡΠ½Π°, ΠΌΠ΅ΠΆΠ΄ΠΈΡΡΠΈΠΏΠ»ΠΈΠ½Π°ΡΠ½ΠΎ ΠΎΡΠΊΡΡΡΠ°, ΠΎΡΠΈΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π° ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ Π½Π° ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΡΡΠΊΡΡΡΡ ΡΠ΅ΠΌΡΠΈ ΠΈ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ ΡΠ΅ΠΌΡΠΈ Ρ Π΄ΡΡΠ³ΠΈΠΌΠΈ ΡΠΎΡΠΈΠ°Π»ΡΠ½ΡΠΌΠΈ ΠΈΠ½ΡΡΠΈΡΡΡΠ°ΠΌΠΈ. ΠΡΠΈ ΡΠ°ΠΊΠΎΠΉ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΡΠΊΠΎΠΉ ΠΎΠΏΡΠΈΠΊΠ΅ Π΄Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»Π΅ΠΉ ΡΠΎΠ½ΠΎΠΌ ΡΡΠ°Π½ΠΎΠ²ΠΈΡΡΡ Π»ΠΈΡΠ½ΠΎΡΡΡ (ΡΡΠΏΡΡΠ³ΠΎΠ² ΠΈ Π΄Π΅ΡΠ΅ΠΉ). Π Β«ΡΠΊΠΎΠ»ΡΠ½ΠΎ-ΠΆΡΡΠ½Π°Π»ΡΠ½Π°ΡΒ» ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΡΡΡ ΡΠΎΡΡΠΈΠΉΡΠΊΠΈΡ
ΡΠΎΡΠΈΠΎΠ»ΠΎΠ³ΠΎΠ² ΡΠ΅ΠΌΡΠΈ ΠΏΡΠΎΡΠ²Π»ΡΠ΅ΡΡΡ ΠΏΠΎ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ Π½Π΅ ΠΊ ΠΎΡΠ΅ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌ, Π° ΠΊ Π·Π°ΡΡΠ±Π΅ΠΆΠ½ΡΠΌ Π°Π²ΡΠΎΡΠ°ΠΌ, ΡΡΠΎ ΡΡΠ΅Π±ΡΠ΅Ρ ΡΡΠΈΠ»Π΅Π½ΠΈΡ ΠΌΠ΅ΠΆΠ΄ΠΈΡΡΠΈΠΏΠ»ΠΈΠ½Π°ΡΠ½ΠΎΠ³ΠΎ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»Π΅ΠΉ ΡΠ΅ΠΌΡΠΈ
Treatment of breast cancer
Compounds of the class of 4-oxo-butenoic acid derivatives are disclosed along with the surprising use property of these compounds as a anti-tumor agents in humans against breast carcinoma, which include: 2-(N\u27-Fluoren-9-ylidene-hydrazino)-5,5-dimethyl-4-oxo-hex-2-enoic acid methyl ester (0F-06), 1-(2,4-Dimethyl-phenyl)-2,4-dihydroxy-3-(4-methyl-benzoyl)-5-oxo-2,5-dihydro-1H-pyrrole-2-carboxylic acid methyl ester (1F-07), 4-(4-Methoxy-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid (3F-10), 4-(4-Chloro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid ethyl ester (3F-11), 2-Hydroxy-4-oxo-4-(2,3,5,6-tetrafluoro-4-methoxy-phenyl)-but-2-enoic acid (3F-15), and 4,4-Dihydroxy-5-(4-methyl-benzoyl)-2-phenyl-2,4-dihydro-pyrazol-3-one (3F-16) as well as some novel derivatives of these compounds claimed (see Table 2). The invention also encompasses a class of the compounds with the novel property of anti-tumor activity against human breast cancer, which includes the following compounds 4-(4-Ethoxy-phenyl)-2-(N\u27-fluoren-9-ylidene-hydrazino)-2-hydroxy-4-oxo-butyric acid methyl ester (0F-13); 2-{N\u27-[1-(4-Chloro-phenyl)-ethylidene]-hydrazino}-4-oxo-4-phenyl-but-2-enoic acid methyl ester (0F-20); 2-(N\u27-Fluoren-9-ylidene-hydrazino)-4-oxo-4-phenyl-but-2-enoic acid methyl ester (1F-04); and 4-Chloro-4-(4-ethoxy-phenyl)-2-(fluoren-9-ylidene-hydrazono)-but-3-enoic acid methyl ester (3F-19)
Treatment of breast cancer
Compounds of the class of 4-oxo-butenoic acid derivatives are disclosed along with the surprising use property of these compounds as a anti-tumor agents in humans against breast carcinoma, which include: 2-(N\u27-Fluoren-9-ylidene-hydrazino)5,5-dimethyl-4-oxo-hex-2-enoic acid methyl ester (OF-06), 1-(2,4-Dimethyl-phenyl)-2,4-dihydroxy-3-(4-methyl-benzoyl)-5-oxo-2,5-dihydro-1H-pyrrole-2-carboxylic acid methyl ester (1F-07), 4-(4-Methoxy-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid (3F-10), 4-(4-Chloro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid ethyl ester (3F-11), 2-Hydroxy-4-oxo-4-(2,3,5,6-tetrafluoro-4-methoxy-phenyl)-but-2-enoic acid (3F-15), and 4,4-Dihydroxy-5-(4-methyl-benzoyl)-2-phenyl-2,4-dihydro-pyrazol-3-one (3F-16) as well as some novel derivatives of these compounds claimed (see Table 2). The invention also encompasses a class of the compounds with the novel property of anti-tumor activity against human breast cancer, which includes the following compounds 4-(4-Ethoxy-phenyl)-2-(N\u27-fluoren-9-ylidene-hydrazino)-2-hydroxy-4-oxo-butyric acid methyl ester (OF-13); 2-{N\u27-[1-(4-Chloro-phenyl)-ethylidene]-hydrazino}-4-oxo-4-phenyl-but-2-enoic acid methyl ester (OF-20); 2-(N\u27-Fluoren-9-ylidene-hydrazino)-4-oxo-4-phenyl-but-2-enoic acid methyl ester (1F-04); and 4-Chloro-4-(4-ethoxy-phenyl)-2-(fluoren-9-ylidene-hydrazono)-but-3-enoic acid methyl ester (3F-19
Treatment of colon cancer
The novel compound of the disclosure is 4-chloro-4-(4-ethoxy-phenyl)-2-(fluoren-9-ylidene-hydrazono)-but-3-enoic acid methyl ester (3F-19), and it alone or in combination with 4-(4-Ethoxy-phenyl)-2-(N\u27-fluoren-9-ylidene-hydrazino)-2-hydroxy-4-oxo-butyric acid methyl ester (OF-13), appears useful in humans as therapeutic means for the eradication of tumors from the human\u27s colon
Treatment of colon cancer
The novel compound of the disclosure is 4-chloro-4-(4-ethoxy-phenyl)-2-(fluoren-9-ylidene-hydrazono)-but-3-enoic acid methyl ester (3F-19), and it alone or in combination with 4-(4-Ethoxy-phenyl)-2-(N\u27-fluoren-9-ylidene-hydrazino)-2-hydroxy-4-oxo-butyric acid methyl ester (OF-13), appears useful in humans as therapeutic means for the eradication of tumors from the human\u27s colon
Methyl esters of substituted 4-OXO-2-butenoic acids for treatment of tuberculosis
A novel class of methyl esters of substituted 4-oxo-2-butenoic acids and their derivatives are disclosed along with the surprising use property of these compounds as a bacteriostatic agents for humans or non-humans against mycobacteria. These compounds include: 4-(4-Ethoxy-phenyl)-2-(N-fluoren-9-ylidene-hydrazino)-4-oxo-but-2-enoic acid methyl ester; 4-(4-Ethoxy-phenyl)-2-(N-fluoren-9-ylidene-hydrazino)-2-hydroxy-4-oxo-but yric acid methyl ester; 2-(4-Bromo-phenylamino)-5,5-dimethyl-4-oxo-hex-2-enoic acid methyl ester; A pharmaceutical composition is disclosed as well as the method of treating human and non-humans infected with M. tuberculosis and related mycobacteria
Study of acute and chronic toxicity of feed additive based on vermiculture
The paper presents the results of study of the toxicity of a feed additive, which includes Leuzea safflower (Rhaponticum carthamoides) and protein obtained from vermiculture. The acute toxicity of the feed additive was studied in 31 SD white rats. It has been established that the acute oral toxicity of the feed additive is above 2500 mg/kg, which makes it possible to classify the feed additive as hazard class 3 and classify it as βmoderately hazardousβ according to GOST 12.1.007-76. The chronic toxicity of the feed additive was studied in 22 SD white rats. The feed additive was administered orally at a dose of 120 and 1200 mg/kg for 30 days. Long-term effects were assessed 14 days after the last introduction of the feed additive. To assess the toxic effects, the effect of the additive on the general condition of the animals, food and water intake was evaluated, blood and urine were analyzed. Complete blood count was carried out by standard methods with the determination of the following parameters: hematocrit, hemoglobin level, the number of erythrocytes, platelets, leukocytes, eosinophils, segmented neutrophils, lymphocytes and monocytes. The study of biochemical parameters of blood was carried out using standard kits for biochemical analysis. The following indicators were determined: ALT, total bilirubin, glucose, creatinine and urea. The urinalysis included the determination of the following indicators: density, leukocytes, nitrites, pH, erythrocytes, protein,Β glucose, ascorbic acid, ketones, urobilinogen, bilirubin. There was no statistically significant difference in blood and urine parameters between the animals of the control and experimental groups. A pathohistological examination of the stomach, liver, kidneys and heart was carried out, which showed the absence of a toxic effect of the feed additive. Local irritant action was studied in pathomorphological studies. It has been established that the feed additive does not have an irritating effect at the injection site. Thus, the feed additive can be used in feeding farm animals and birds at the recommended dose
Π ΠΎΠ»Ρ ΠΎΠΊΠΈΡΠ»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΡΡΡΠ΅ΡΡΠ° Π² ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ ΠΊΠ°ΡΠ΄ΠΈΠΎΠ΄Π΅ΠΏΡΠ΅ΡΡΠΈΠΈ ΠΏΡΠΈ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΠΈΠ·ΠΎΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΠ΅ΡΠ΅ΠΏΠ½ΠΎ-ΠΌΠΎΠ·Π³ΠΎΠ²ΠΎΠΉ ΡΡΠ°Π²ΠΌΠ΅ (ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅)
Objective: to study the role of oxidative stress in the development of cardiac structural and metabolic disorders in severe isolated brain injury (BI). Materials and methods. The impact of BI on the parameters of serum chemilu-minescence and the contractility of isolated rat hearts were studied in experiments on 66 outbred male albino rats, as described by E. T. Fallen et al. Lipid peroxidation processes were inhibited, by intraperitoneally injecting the antioxidant carnosine (100 mg/kg) 1 and 24 hours before or just after BI. Results. The rate of free radical processes rose an hour after severe isolated BI, which was associated with the indirect signs of cardiomyocitic membrane damages, depressed rat heart contractility, and their diminished resistance to hypoxia, reoxygenation, and exercise by high rhythm. Administration of carnosine to the animals favored the normalization of chemluminescent values with the high overall antioxidative capacity of serum. The effect of the agent depended on the time of its use and it was high when carnosine was injected 1 and 24 hours before injury. At the stage of reoxygenation after the hypoxic test, there was a significant increase in evolving pressure, the rate of left ventricular myocardial contraction and relaxation, and a reduction in AsAT activity in all coronary duct tests, as compared with the controls. A negative correlation was found between the burst amplitude and the myocardial relaxation rate in the animals receiving the agent. Conclusion. Improved cardiac contractility and increased capacities of the mechanisms responsible for Ca2+ transport due to the use of the antioxidant carnosine allow one to state that oxidative stress is one of the pathogenetic factors of cardiac depression in severe isolated BI. Key words: brain injury, heart, oxidative stress, carnosine.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΠΎΠ»ΠΈ ΠΎΠΊΠΈΡΠ»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΡΡΡΠ΅ΡΡΠ° Π² ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ ΡΡΡΡΠΊΡΡΡΠ½ΠΎ-ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΈΡ
Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ ΡΠ΅ΡΠ΄ΡΠ° ΠΏΡΠΈ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΠΈΠ·ΠΎΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΠ΅ΡΠ΅ΠΏΠ½ΠΎ-ΠΌΠΎΠ·Π³ΠΎΠ²ΠΎΠΉ ΡΡΠ°Π²ΠΌΠ΅ (Π§ΠΠ’). ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Ρ
Π½Π° 66 Π±Π΅Π»ΡΡ
Π±Π΅ΡΠΏΠΎΡΠΎΠ΄Π½ΡΡ
ΠΊΡΡΡΠ°Ρ
-ΡΠ°ΠΌΡΠ°Ρ
ΠΈΠ·ΡΡΠ΅Π½ΠΎ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π§ΠΠ’ Π½Π° ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Ρ
Π΅ΠΌΠΈΠ»ΡΠΌΠΈΠ½Π΅ΡΡΠ΅Π½ΡΠΈΠΈ ΡΡΠ²ΠΎΡΠΎΡΠΊΠΈ ΠΊΡΠΎΠ²ΠΈ ΠΈ ΡΠΎΠΊΡΠ°ΡΠΈΠΌΠΎΡΡΡ ΠΈΠ·ΠΎΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΡΠ΅ΡΠ΄Π΅Ρ ΠΊΡΡΡ ΠΏΠΎ E. T. Fallen et al. ΠΡΠΎΡΠ΅ΡΡΡ Π»ΠΈΠΏΠΎΠΏΠ΅ΡΠΎΠΊΡΠΈΠ΄Π°-ΡΠΈΠΈ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΠ²Π°Π»ΠΈ ΠΏΡΡΠ΅ΠΌ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π²Π½ΡΡΡΠΈΠ±ΡΡΡΠΈΠ½Π½ΠΎ Π·Π° 24 ΠΈ 1 Ρ Π΄ΠΎ ΡΡΠ°Π²ΠΌΡ ΠΈΠ»ΠΈ Π½Π΅ΠΏΠΎΡΡΠ΅Π΄ΡΡΠ²Π΅Π½Π½ΠΎ ΠΏΠΎΡΠ»Π΅ Π§ΠΠ’ Π°Π½ΡΠΈΠΎΠΊΡΠΈΠ΄Π°Π½ΡΠ° ΠΊΠ°ΡΠ½ΠΎΠ·ΠΈΠ½Π° (100 ΠΌΠ³/ΠΊΠ³). Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π§Π΅ΡΠ΅Π· 1 Ρ ΠΏΠΎΡΠ»Π΅ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΠΈΠ·ΠΎΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ Π§ΠΠ’ Π²ΠΎΠ·ΡΠ°ΡΡΠ°Π»Π° ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΠΎΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠ΅ΡΡΠΎΠ², ΡΡΠΎ ΡΠΎΡΠ΅ΡΠ°Π»ΠΎΡΡ Ρ ΠΊΠΎΡΠ²Π΅Π½Π½ΡΠΌΠΈ ΠΏΡΠΈΠ·Π½Π°ΠΊΠ°ΠΌΠΈ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠΉ ΠΌΠ΅ΠΌΠ±ΡΠ°Π½ ΠΊΠ°ΡΠ΄ΠΈΠΎΠΌΠΈΠΎΡΠΈΡΠΎΠ², Π΄Π΅ΠΏΡΠ΅ΡΡΠΈΠ΅ΠΉ ΡΠΎΠΊΡΠ°ΡΠΈΠΌΠΎΡΡΠΈ ΡΠ΅ΡΠ΄Π΅Ρ ΠΊΡΡΡ ΠΈ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΈΡ
ΡΡΡΠΎΠΉΡΠΈΠ²ΠΎΡΡΠΈ ΠΊ Π³ΠΈΠΏΠΎΠΊΡΠΈΠΈ, ΡΠ΅ΠΎΠΊ-ΡΠΈΠ³Π΅Π½Π°ΡΠΈΠΈ ΠΈ Π½Π°Π³ΡΡΠ·ΠΊΠ΅ ΡΠΈΡΠΌΠΎΠΌ Π²ΡΡΠΎΠΊΠΎΠΉ ΡΠ°ΡΡΠΎΡΡ. ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ ΠΆΠΈΠ²ΠΎΡΠ½ΡΠΌ ΠΊΠ°ΡΠ½ΠΎΠ·ΠΈΠ½Π° ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΠΎΠ²Π°Π»ΠΎ Π½ΠΎΡΠΌΠ°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ Ρ
Π΅ΠΌΠΈΠ»ΡΠΌΠΈΠ½Π΅ΡΡΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° Π½Π° ΡΠΎΠ½Π΅ Π²ΡΡΠΎΠΊΠΎΠΉ ΠΎΠ±ΡΠ΅ΠΉ Π°Π½ΡΠΈΠΎΠΊΡΠΈΠ΄Π°Π½ΡΠ½ΠΎΠΉ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ ΡΡΠ²ΠΎΡΠΎΡΠΊΠΈ ΠΊΡΠΎΠ²ΠΈ. ΠΡΡΠ΅ΠΊΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π·Π°Π²ΠΈΡΠ΅Π» ΠΎΡ ΡΡΠΎΠΊΠΎΠ² Π΅Π³ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΈ Π±ΡΠ» Π±ΠΎΠ»ΡΡΠΈΠΌ ΠΏΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ ΠΊΠ°ΡΠ½ΠΎΠ·ΠΈΠ½Π° Π·Π° 24 ΠΈ 1 Ρ Π΄ΠΎ ΡΡΠ°Π²ΠΌΡ. ΠΠ° ΡΡΠ°ΠΏΠ΅ ΡΠ΅ΠΎΠΊΡΠΈΠ³Π΅Π½Π°ΡΠΈΠΈ ΠΏΠΎΡΠ»Π΅ Π³ΠΈΠΏΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠΎΠ±Ρ Π±ΡΠ»ΠΎ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠ΅ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅, ΠΏΠΎ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ ΠΊ Π³ΡΡΠΏΠΏΠ΅ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ, ΡΠ°Π·Π²ΠΈΠ²Π°Π΅ΠΌΠΎΠ³ΠΎ Π΄Π°Π²Π»Π΅Π½ΠΈΡ, ΡΠΊΠΎΡΠΎΡΡΠΈ ΡΠΎΠΊΡΠ°ΡΠ΅Π½ΠΈΡ ΠΈ ΡΠ°ΡΡΠ»Π°Π±Π»Π΅Π½ΠΈΡ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° Π»Π΅Π²ΠΎΠ³ΠΎ ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠΊΠ°, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΡΠΠ’ Π²ΠΎ Π²ΡΠ΅Ρ
ΠΏΡΠΎΠ±Π°Ρ
ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΎΠΊΠ°. ΠΡΠ»Π° Π²ΡΡΠ²Π»Π΅Π½Π° ΠΎΡΡΠΈΡΠ°ΡΠ΅Π»ΡΠ½Π°Ρ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΎΠ½Π½Π°Ρ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡ ΠΌΠ΅ΠΆΠ΄Ρ Π°ΠΌΠΏΠ»ΠΈΡΡΠ΄ΠΎΠΉ Π²ΡΠΏΡΡΠΊΠΈ ΠΈ ΡΠΊΠΎΡΠΎΡΡΡΡ ΡΠ°ΡΡΠ»Π°Π±Π»Π΅Π½ΠΈΡ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π£Π»ΡΡΡΠ΅Π½ΠΈΠ΅ ΡΠΎΠΊΡΠ°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠΈ ΡΠ΅ΡΠ΄Π΅Ρ ΡΡΠ°Π²ΠΌΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΊΡΡΡ ΠΈ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΠΌΠΎΡΠ½ΠΎΡΡΠΈ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠΎΠ², ΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΡΡ
Π·Π° ΡΡΠ°Π½ΡΠΏΠΎΡΡ Π‘Π°2+, ΠΏΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ Π°Π½ΡΠΈΠΎΠΊΡΠΈΠ΄Π°Π½ΡΠ° ΠΊΠ°ΡΠ½ΠΎΠ·ΠΈΠ½Π° ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΡΠ²Π΅ΡΠΆΠ΄Π°ΡΡ, ΡΡΠΎ ΠΎΠΊΠΈΡΠ»ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΡΡΡΠ΅ΡΡ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ· ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ² ΠΊΠ°ΡΠ΄ΠΈΠΎΠ΄Π΅ΠΏΡΠ΅ΡΡΠΈΠΈ ΠΏΡΠΈ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΠΈΠ·ΠΎΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ Π§ΠΠ’. ΠΠ»ΡΡΠ΅Π²ΡΠ΅ ΡΠ»ΠΎΠ²Π°: ΡΠ΅ΡΠ΅ΠΏΠ½ΠΎ-ΠΌΠΎΠ·Π³ΠΎΠ²Π°Ρ ΡΡΠ°Π²ΠΌΠ°, ΡΠ΅ΡΠ΄ΡΠ΅, ΠΎΠΊΠΈΡΠ»ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΡΡΡΠ΅ΡΡ, ΠΊΠ°ΡΠ½ΠΎΠ·ΠΈΠ½